How Computational Biology is Transforming Drug R&D

Goldman Sachs Exchanges

Goldman Sachs

Business

4.4 • 1K Ratings

🗓️ 3 March 2020

⏱️ 10 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

The latest episode of Exchanges at Goldman Sachs premieres a new monthly feature: An examination of a topic at the center of conversations in the venture-capital community. This week, Goldman Sachs Research’s Heath Terry explores the growing world of computational biology—using the power of big data to revolutionize drug discovery, disease prevention and cancer detection. Terry talked to VCs like Lux Capital’s Zavain Dar, who invests in emerging science and technology firms. “It feels like we’re at the precipice of what I think will be a multi-decade revolution in how biology and chemistry are fundamentally practiced,” explains Dar. Terry also spoke with James Field, CEO of computational-biology startup LabGenius, which is using machine learning to more easily identify useful proteins for the human body. “If we can deploy technology in building out some discovery platforms in a way that the learnings compound over time,” says Field, “then it will dramatically change the economics of discovering and developing drug molecules.”

Transcript

Click on a timestamp to play from that location

0:00.0	Welcome to exchanges of Goldman Sachs. I'm Jake Stewart, global head of corporate communications here at the firm. Today I'm joined Stewart Global Head of Corporate Communications here at the firm.
0:13.0	Today I'm joined by Heath Terry of our Global Investment Research Division.
0:17.4	Heath is a close observer of venture capital, both the startups that are seeking it
0:22.1	and the investors who are providing it.
0:24.7	Once a month Heath publishes a report called Venture Capital Horizons, where he explores topics
0:29.6	at the center of conversations in the VC community.
0:32.6	This month, Heath is going to take us
0:34.4	into the world of computational biology
0:37.0	in an audio segment he produced for the podcast.
0:39.0	Heath, thanks for being here.
0:40.2	Thanks for having you, Jake.
0:41.2	Before we dive into our first episode, why don't you tell us a little bit, Heath about
0:44.6	your own background, how you got here and what you do here at Goldman?
0:47.6	I've been with the firm about nine years now.
0:50.9	My primary job is to head our global internet research coverage but I also
0:56.7	built the the venture capital horizons group out of the focus that we have on early
1:02.3	stage companies and venture capital.
1:04.8	And how do you discover the companies, entrepreneurs, and the topics that you cover?
1:08.8	I cover the internet sector within investment research and so the competitors, the disruptive threats
1:15.9	to those companies within technology
1:17.9	have always been not the incumbent technology companies, but the venture-backed startups, the guys in the garage that were always going to be the next big thing to come down the the pipe from a technology standpoint from a competition standpoint.
1:34.0	So we've always kept a really close eye on venture capital and VCH sort of evolved out of that.
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Goldman Sachs, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Goldman Sachs and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.